This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.
Lighting the Way: Exploring the Potential of Photobiomodulation for Dry AMD Treatment
8
episodes
0.75 program credits1h 00m
Details
Presenters
Target Audience
This certified CME activity is designed for retina specialists.
Grantor Statement
This activity is supported by an independent educational grant from LumiThera, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Relate the mechanism of photobiomodulation to its clinical relevance in treating dry AMD.
- Assess the safety and efficacy of photobiomodulation therapy for dry AMD, based on clinical trial data.
- Identify patient characteristics that may indicate suitability for photobiomodulation therapy, based on clinical evidence.
- Examine how photobiomodulation therapy could be incorporated into the current dry AMD management paradigm.
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty
Janis T. Eells, Ph.D
Professor
Department of Biomedical Sciences-Health Care Administration
College of Health Professions and Sciences
University of Wisconsin-Milwaukee
Milwaukee, WI
Marion R. Munk, MD, Ph.D
Augenarzt-Praxisgemeinschaft Gutblick AG
Adjunct Professor of Ophthalmology
Northwestern University
Chicago, IL
David S. Boyer, MD
Retina-Vitreous Associates Medical Group
Adjunct Clinical Professor of Ophthalmology
University of Southern California
Los Angeles, CA
Diana V. Do, MD
Vice Chair of Clinical Affairs
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Stanford, CaliforniaDisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Janis T. Eells, Ph.D, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: LumiThera, Inc. and Multi Radiance. Research Support: NIH/NEI R44-EY025892-05 and NIH/NEI R43-EY025892.
Marion Munk, MD, Ph.D, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie Inc., Apellis Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Isarna Therapeutics, LumiThera, Inc., RetinAI, Roche, Zeiss.
David S. Boyer, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4D Molecular Therapeutics (4DMT), AbbVie Inc., ADARx Pharmaceuticals, Adverum Biotechnologies, AiViva Biopharma, Alcon Vision, LLC, Aldeyra Therapeutics, Alimera Sciences, Alkahest, Allegro, Allgenesis, Alumis, Amgen, Amaros, Inc, Annexon Biosciences, Apellis Pharmaceuticals, Inc., Applied Genetec Technologies Corp (AGTC), AsclepiX Therapeutics, Ashvattha Therapeutics, Astellas Pharma Global Development, Inc., Aviceda Therapeutics, Bausch & Lomb, Bayer, Belite Bio, BioCryst Pharmaceuticals, Bionic Vision Technologie, Biovisics Medical, Inc, Boehringer-Ingelheim Pharmaceuticals, Inc., Clearside Biomedical, EyePoint Pharmaceuticals, Frontera Therapeutics, Genentech, Inc., Glaukos, Janssen Biotech, Inc., jCyte, Kriya Therapeutics, Kyowa Kirin, Inc., Lineage Cell, LumiThera, Inc., Nanoscope Therapeutics, Neurotech Pharmaceuticals, Inc., Novartis Ophthalmics Corporation, Ocugen, Inc., Oculis SA, Ocuphire Pharma, OcuTerra Therapeutics, Ocutrx Vision Technologies, Opthea, Optos, Ora Inc., Palatin Technologies, Inc., Pfizer Inc., Perceive Biotherapeutics, Ray Therapeutics, Regeneron Pharmaceuticals inc., RegenxBio, Rezolute, Ripple Therapeutics, Samsung Bioepis Co. Ltd., Sanofi, Science Branding, Smilebiotek Zhuhai Limited, Stealth BioTherapeutics, Sun Pharmaceuticals, Thea, Unity Biotech, Valo Health, Vanotech Ltd., Visgenx, Inc., Vitranu, Inc., Vitro Biopharma, and Viva Vision Biotech. Stocks: Allegro.
Diana V. Do, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Apellis Pharmaceuticals, Inc., Astellas Pharma Global Development, Belite Bio, EyePoint Pharmaceuticals, Kodiak Sciences, LumiThera, Inc., Malinkrodt, Ocular Therapeutix, and Regeneron Pharmaceuticals Inc.Research Support: Belite Bio, LumiThera, Inc., Ocular Therapeutix, Regeneron Pharmaceuticals Inc., and Regenxbio.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or LumiThera.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
